Group 1: Xiaomi Group Performance - Xiaomi Group reported a revenue of 111.29 billion yuan for Q1 2025, a year-on-year increase of 47.4% [1] - The gross profit reached 25.41 billion yuan, up 50.96% year-on-year [1] - Shareholder profit attributable to the company was 10.92 billion yuan, reflecting a significant increase of 161.22% year-on-year [1] - The average selling price of Xiaomi's smart electric vehicles was 238,301 yuan, with 75,869 units of the Xiaomi SU 7 series delivered [1] - Revenue from smart home appliances grew by 113.8% year-on-year, with air conditioner shipments exceeding 1.1 million units, and washing machine shipments surpassing 740,000 units, both achieving over 65% growth [1] Group 2: User Growth - Global monthly active users reached 718.8 million in March 2025, a year-on-year growth of 9.2% [2] - Monthly active users in mainland China reached 181.1 million, marking a 12.9% increase year-on-year [2] Group 3: HYBE and Tencent Transaction - HYBE sold all its shares in SM Entertainment to Tencent for approximately 12.9 billion yuan [8] - Following this transaction, Tencent Music Entertainment Group will become the second-largest shareholder of SM Entertainment, just behind Kakao [8] Group 4: Kuaishou Financial Results - Kuaishou reported a revenue of 32.61 billion yuan for Q1 2025, a year-on-year increase of 10.9% [14] - The adjusted net profit was 4.58 billion yuan, reflecting a growth of 4.4% year-on-year [14] - The company's AI product, Keling AI, generated over 150 million yuan in revenue during Q1 2025 [15] Group 5: Regulatory Approvals - Rongchang Bio received approval from the National Medical Products Administration for its drug Tai Tasi Pu (brand name: Tai Ai) for treating generalized myasthenia gravis in China [16] - Junshi Biosciences received approval for its monoclonal antibody injection for new indications, becoming the first domestically approved PCSK9-targeted drug for patients intolerant to statins [17]

Group 1 - Guangdian Electric's wholly-owned subsidiary plans to sell 5.91% stake in Shanghai Winshun Electric Technology Co., Ltd. to Yapp Automotive Parts Co., Ltd. for 62.63 million yuan, aiming to optimize asset structure [1] - Anhui Natural Gas received approval for the registration of 500 million yuan short-term financing bonds and 600 million yuan medium-term notes, valid for two years [1] - Kirin Security received government subsidies totaling 6.48 million yuan, which are related to revenue [2] Group 2 - Junshi Biosciences received approval for two new indications for its self-developed drug, Oncorhynchus monoclonal antibody injection, targeting adult patients with heterozygous familial hypercholesterolemia and non-familial hypercholesterolemia [3] - China Resources Double Crane's subsidiary passed GMP compliance inspection for small and large volume injection production lines [4] - Nanjing Public Utilities' board approved the absorption and merger of its wholly-owned subsidiary, Nanjing Jinguang Industry Co., Ltd. [7] Group 3 - Boya Bio received drug registration certificate for human immunoglobulin (pH4) in the Dominican Republic, valid until August 12, 2029 [8] - Jizhi Co. announced that its controlling shareholder and actual controller committed not to reduce their shareholdings until December 31, 2025 [9] - Yuhua Tian won a bid for the integrated urban management project in Lanzhou City, with a total service subsidy of 353 million yuan [10] Group 4 - Anke Rui obtained five invention patent certificates related to various energy management and control technologies [11] - Kebo Da's wholly-owned subsidiary plans to acquire 100% of Czech IMI Company for approximately 9.43 million euros to enhance global production layout [13] - Yantian Port announced a cash dividend of 1.30 yuan per 10 shares, totaling 676 million yuan [14] Group 5 - Huawang Technology plans to distribute a cash dividend of 0.45 yuan per share and a capital reserve increase of 0.20 shares per share [15] - Kabe Yi established a wholly-owned subsidiary in Japan to enhance its business layout [16] - Dongcheng Pharmaceutical's subsidiary received approval for the marketing of sodium fluoride injection, a PET radiopharmaceutical [18] Group 6 - Huaxin New Materials' subsidiary received two utility model patent certificates for innovative devices [19] - Lingang Steel's new 2290 cubic meter blast furnace has been successfully put into operation [21] - Xinlitai received drug registration certificate for Sacubitril/Valsartan tablets, the first of its kind in China [23] Group 7 - Aike Co.'s subsidiary received project designation notices from multiple clients for electric drive platform components [25] - Tonghe Pharmaceutical received drug registration certificate for Apixaban in South Korea [26] - Junting Hotel signed a cooperation agreement with Choice Hotels for exclusive brand usage in mainland China [28] Group 8 - Guangdong Hongtu plans to establish a wholly-owned subsidiary in Zhengzhou to enhance market layout [30] - Yuheng Pharmaceutical signed a joint promotion agreement for Pemafibrate tablets with Xinghe Pharmaceutical [31] - Chongqing Steel terminated the absorption and merger of its wholly-owned subsidiary, citing strategic advantages of independent operation [33] Group 9 - Jihong Co. announced the listing of its H-shares on the Hong Kong Stock Exchange [34] - Deshi Co. announced plans for shareholders to reduce their holdings by up to 0.3% [36] - Xinhai Medical's subsidiary received medical device registration for a dialysis fluid filter [42]

君实生物：昂戈瑞西单抗注射液新适应症上市申请获得批准 智通财经5月27日电，君实生物(688180.SH)公告称，公司收到国家药监局核准签发的《药品注册证 书》，昂戈瑞西单抗注射液（商品名：君适达®）用于杂合子型家族性高胆固醇血症（HeFH）的成人 患者以及他汀类药物不耐受或禁忌使用的患者中，单独或与依折麦布联合用药用于非家族性高胆固醇血 症和混合型血脂异常的成人患者的新适应症上市申请获得批准。昂戈瑞西单抗成为首个获批用于他汀不 耐受人群的国产PCSK9靶点药物。 ...